

A symposium sponsored by Cubist at the 20th Congress of the European Association of Hospital Pharmacists (EAHP)

Benefits of Antibiotic Stewardship in the Management of Acute Infections

Thursday, 26 March 2015, 12:00-13:30
Hall 6, CCH - Congress Center Hamburg

INVITATION

Lunch bags will be provided

Dear delegate,

We are delighted to invite you to a satellite symposium sponsored by Cubist entitled, *Benefits of Antibiotic Stewardship in the Management of Acute Infections*, at 12:00-13:30 on **26 March 2015** at the 20th Congress of the European Association of Hospital Pharmacists in Hamburg, Germany. A lunch bag will be provided for each delegate.

This symposium has been accredited in England, Scotland, and Wales by the **Royal Pharmaceutical Society (RPS)**, to promote professional development in the fields of pharmacy, public health, and medicines management.

The symposium will highlight the efficacy and safety considerations of managing acute infections in the hospital setting, focusing on antibiotic stewardship and strategies for reducing length of hospital stays for patients. Appropriate prescribing can reduce the risk of bacteria developing resistance to antibiotics, therefore improving clinical outcomes for patients. Furthermore, the timely application of switching patients from intravenous to oral antibiotics or to outpatient parenteral antibiotic therapy, and early discharge strategies have the potential to improve hospital bed capacity, reduce costs, improve patient satisfaction, reduce the incidence of healthcare-associated infections, and allow for the reallocation of hospital resources.

We look forward to welcoming you to this symposium.

With kind regards,

Jonathan Cooke, BPharm, MPharm, PhD, MRPharmS
University of Manchester, UK

Agenda

- | | | |
|--------------|--|---|
| 12:00 | Chairman's welcome and introduction | Jonathan Cooke
<i>Manchester, UK</i> |
| 12:20 | Antibiotic stewardship programs - How do they promote a "safer" environment? | Christian Eckmann
<i>Hannover, Germany</i> |
| 12:40 | Intravenous to oral switching, OPAT, and early discharge | Mark Gilchrist
<i>London, UK</i> |
| 13:00 | The role of new antibiotics in the treatment of severe infections - Safety and efficacy features | Christian Eckmann
<i>Hannover, Germany</i> |
| 13:15 | Q&A with panel discussion | All |



CUBIST

Cubist, wholly owned subsidiary of
Merck & Co., Inc., Kenilworth, NJ, USA